O	0	10	Evaluation
O	11	13	of
B-intervention	14	24	Lymphedema
I-intervention	25	35	Prevention
I-intervention	36	44	Protocol
O	45	47	on
O	48	55	Quality
O	56	58	of
O	59	63	Life
O	64	69	among
B-eligibility	70	76	Breast
I-eligibility	77	83	Cancer
I-eligibility	84	92	Patients
I-eligibility	93	97	with
I-eligibility	98	108	Mastectomy
O	108	109	.

B-condition	110	120	Lymphedema
O	121	123	is
O	124	125	a
O	126	136	widespread
O	137	149	complication
O	150	155	after
O	156	163	surgery
O	164	166	or
O	167	176	radiation
O	177	184	therapy
O	185	188	due
O	189	191	to
O	192	195	the
O	196	202	damage
O	203	206	and
O	207	218	obstruction
O	219	221	of
O	222	225	the
O	226	235	lymphatic
O	236	243	vessels
O	243	244	.

O	245	246	A
O	247	252	study
O	253	256	was
O	257	266	conducted
O	267	269	to
O	270	276	assess
O	277	280	the
O	281	294	effectiveness
O	295	297	of
O	298	308	lymphedema
O	309	319	prevention
O	320	328	protocol
O	329	331	on
O	332	339	quality
O	340	342	of
O	343	347	life
O	348	353	among
O	354	360	breast
O	361	367	cancer
O	368	376	patients
O	377	381	with
O	382	392	mastectomy
O	393	395	at
O	396	397	a
O	398	406	selected
O	407	415	hospital
O	416	418	in
B-location	419	424	Tamil
I-location	425	429	Nadu
O	429	430	.

O	431	441	Objectives
O	442	444	of
O	445	448	the
O	449	454	study
O	455	459	were
O	460	462	to
O	463	471	identify
O	472	475	the
O	476	482	effect
O	483	485	of
O	486	496	lymphedema
O	497	507	prevention
O	508	516	protocol
O	517	519	on
O	520	530	lymphedema
O	531	541	occurrence
O	542	545	and
O	546	553	quality
O	554	556	of
O	557	561	life
O	561	562	.

O	563	564	A
O	565	577	quantitative
O	578	586	research
O	587	595	approach
O	596	598	of
O	599	604	quasi
O	605	617	experimental
O	618	621	non
O	621	622	-
O	622	632	equivalent
O	633	637	with
O	638	645	control
O	646	651	group
O	652	658	before
O	659	660	-
O	660	665	after
O	666	672	design
O	673	674	(
O	674	677	Non
O	678	688	randomized
O	688	689	)
O	690	693	was
O	694	698	used
O	698	699	.

O	700	703	The
O	704	716	investigator
O	717	720	had
O	721	729	included
B-total-participants	730	733	120
O	734	746	participants
O	747	749	by
O	750	755	using
O	756	765	purposive
O	766	774	sampling
O	775	784	technique
O	785	790	which
O	791	799	included
B-intervention-participants	800	802	60
O	803	807	each
O	808	810	in
O	811	816	study
O	817	820	and
O	821	831	comparison
O	832	837	group
O	837	838	.

O	839	842	Pre
O	843	847	test
O	848	851	was
O	852	856	done
O	857	863	before
O	864	867	the
O	868	880	intervention
O	881	883	of
O	884	894	lymphedema
O	895	905	prevention
O	906	914	protocol
O	915	917	to
O	918	922	both
O	923	933	comparison
O	934	937	and
O	938	943	study
O	944	949	group
O	950	962	participants
O	962	963	.

O	964	974	Lymphedema
O	975	985	prevention
O	986	994	protocol
O	995	998	was
O	999	1010	implemented
O	1011	1014	for
O	1015	1020	study
O	1021	1026	group
O	1027	1034	whereas
B-control	1035	1045	comparison
I-control	1046	1051	group
I-control	1052	1060	received
I-control	1061	1068	routine
I-control	1069	1073	care
O	1073	1074	.

O	1075	1079	Post
O	1080	1085	tests
O	1086	1087	1
O	1087	1088	,
O	1089	1090	2
O	1090	1091	,
O	1092	1093	3
O	1093	1094	,
O	1095	1098	and
O	1099	1100	4
O	1101	1105	were
O	1106	1110	done
O	1111	1113	by
O	1114	1119	using
O	1120	1123	the
O	1124	1134	structured
O	1135	1148	questionnaire
O	1149	1151	at
O	1152	1156	10th
O	1157	1160	day
O	1160	1161	,
O	1162	1166	30th
O	1166	1167	,
O	1168	1172	60th
O	1173	1176	and
O	1177	1181	90th
O	1182	1186	post
O	1187	1196	operative
O	1197	1200	day
O	1201	1213	respectively
O	1213	1214	.

O	1215	1223	Subjects
O	1223	1224	'
O	1225	1234	responses
O	1235	1239	were
O	1240	1245	coded
O	1246	1249	and
O	1250	1263	statistically
O	1264	1272	analyzed
O	1273	1275	by
O	1276	1281	using
O	1282	1293	descriptive
O	1294	1297	and
O	1298	1309	inferential
O	1310	1320	statistics
O	1320	1321	.

O	1322	1325	The
O	1326	1336	comparison
O	1337	1339	of
B-outcome	1340	1347	quality
I-outcome	1348	1350	of
I-outcome	1351	1355	life
O	1356	1363	between
O	1364	1369	study
O	1370	1373	and
O	1374	1384	comparison
O	1385	1390	group
O	1391	1395	over
O	1396	1397	a
O	1398	1404	period
O	1405	1407	of
O	1408	1412	time
O	1413	1417	were
O	1418	1431	statistically
O	1432	1443	significant
O	1444	1446	at
O	1447	1448	p
O	1448	1449	<
O	1450	1451	0
O	1451	1452	.
O	1452	1455	001
O	1456	1463	whereas
B-outcome	1464	1474	lymphedema
I-outcome	1475	1485	occurrence
O	1486	1489	was
O	1490	1501	significant
O	1502	1504	at
O	1505	1506	p
O	1506	1507	<
O	1508	1509	0
O	1509	1510	.
O	1510	1512	01
O	1512	1513	.

O	1514	1517	The
O	1518	1523	early
O	1524	1533	execution
O	1534	1536	of
O	1537	1547	preventive
O	1548	1556	measures
O	1557	1559	of
O	1560	1570	lymphedema
O	1571	1579	prevents
O	1580	1583	the
O	1584	1594	lymphedema
O	1595	1605	occurrence
O	1606	1609	and
O	1610	1618	promotes
O	1619	1622	the
O	1623	1630	quality
O	1631	1633	of
O	1634	1638	life
O	1639	1644	among
O	1645	1653	patients
O	1654	1663	undergone
O	1664	1674	mastectomy
O	1674	1675	.
